Comment from Anonymous
AnonymousSupportIndividual
Summary: The commenter supports the FDA's efforts to expand regulatory pathways for scientifically validated alternatives to animal testing, such as organ-on-chip technology and computational models. They argue that these New Approach Methodologies (NAMS) improve translational relevance and promote more ethical scientific practices.
I support the FDA continuing to expand clear regulatory pathways for scientifically validated alternatives to animal testing during drug development. Human-relevant methods such as human cell-based testing, organ-on-chip technology, and computational models have the potential to improve translational relevance while reducing reliance on animal studies. I encourage the FDA to continue modernizing its approach and supporting the responsible evaluation and acceptance of validated New Approach Methodologies (NAMS). I believe this is of great importance both scientifically and to move science into a realm of ethical behavior.